A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC

计划入组 200 人 · 首次发布于 2020 年 9 月 16 日

Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)

计划入组 120 人 · 首次发布于 2022 年 5 月 31 日

Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET

计划入组 10 人 · 首次发布于 2024 年 7 月 1 日

DNA Damage Response (Schrödinger)

DNA Damage Response(VRise Therapeutics)

DDT-1

Response Biomedical Corp.

Canada

DNA International Hospital

Vietnam

Immune Response Biopharma, Inc.

United States

Aprea Therapeutics Reports Promising Early Clinical Data for DNA Damage Response Inhibitors

Rakovina Therapeutics Secures $4M Strategic Financing to Advance AI-Powered Cancer Drug Discovery Platform

Rakovina Therapeutics Advances Novel AI-Discovered PARP1 and ATR Inhibitors for Hard-to-Treat Cancers